Juvenile Arthritis News

Patients with juvenile idiopathic arthritis who receive baricitinib demonstrate a “significantly” longer time to disease flare vs. placebo, according to data published in The Lancet.

Infants who demonstrate microbiome dysregulation may be at a higher risk for juvenile idiopathic arthritis, according to data published in eBioMedicine.

A program using cognitive behavioral and mindfulness meditation techniques demonstrated early potential to ease fatigue, depression and pain symptoms in childhood-onset systemic lupus erythematosus, according to researchers.

SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here.

Knee acoustic emissions may be an “inexpensive and easy-to-use” biomarker to help differentiate between patients with and without juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

AUSTIN, Texas — Research in genetics as it relates to rheumatologic diseases has a long way to go, but there are steps providers can take to translate current knowledge into actionable patient care, a presenter said.

Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the June issue, which is led by a cover story on pediatric rheumatology workforce shortage concerns.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

The field of pediatric rheumatology is at a crossroads.

There is “wide variation” in the way clinicians measure and report the physician’s global assessment of disease activity in patients with juvenile idiopathic arthritis, according to data published in Rheumatology.